Marshall Wace, LLP Ventyx Biosciences, Inc. Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
A detailed history of Marshall Wace, LLP transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 2,396,823 shares of VTYX stock, worth $6.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,396,823Holding current value
$6.3 Million% of portfolio
0.01%Shares
6 transactions
Others Institutions Holding VTYX
# of Institutions
120Shares Held
48.4MCall Options Held
16.2KPut Options Held
40.6K-
Black Rock Inc. New York, NY4.77MShares$12.5 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY4.54MShares$11.9 Million1.63% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.23MShares$11.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.16MShares$8.32 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$8.15 Million0.23% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $149M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...